Extended Data Fig. 3: Dose escalation schema.
From: The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemia
The revumenib dose was adjusted based on the body surface area (BSA) for patients weighing less than 40 kg as indicated for each corresponding dose level shown in parentheses. CYP3A4i, cytochrome P450 3A4 inhibitor; q12h, every 12 h; R/R, relapsed or refractory.
